CSL (OTCMKTS:CSLLY) Raised to “Buy” at Jefferies Financial Group

CSL (OTCMKTS:CSLLYGet Rating) was upgraded by analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued on Friday, The Fly reports.

CSL Price Performance

OTCMKTS:CSLLY opened at $92.53 on Friday. CSL has a one year low of $85.07 and a one year high of $117.24. The stock has a 50-day simple moving average of $100.68 and a 200 day simple moving average of $97.93. The company has a current ratio of 2.32, a quick ratio of 3.43 and a debt-to-equity ratio of 0.35.

About CSL

(Get Rating)

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants.

Read More

The Fly logo

Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.